Inve US ▾
CHCHE

Chemed (CHE) Q4 FY25 earnings call: guidance and Q&A

Earnings call· Dec 2025 (Q4 FY25)· Health Care· Feb 26, 2026

Source: earnings call transcript

Executive summary

Chemed Q4 FY25 — VITAS Medicare Cap mitigated, Roto-Rooter faces billing and lead generation challenges

Chemed reported a challenging Q4 FY25, missing expectations due to specific operational headwinds at both VITAS and Roto-Rooter. VITAS successfully mitigated its Florida Medicare Cap risk by increasing short-stay admissions, which temporarily compressed revenue and EBITDA margins. Roto-Rooter faced revenue declines and margin pressure from increased water restoration write-offs and higher marketing costs for lead generation. Management views 2026 as a transition year, with financial results expected to build in the second half as strategic initiatives take hold.

Highlights

5
  • VITAS Florida Medicare Cap position improved by almost $25 million in Q4 FY25 compared to 2025, with no billing limitation accrued for Florida in Q4 FY25.

  • VITAS admissions increased 6% YoY to 17,419 in Q4 FY25.

  • VITAS received a Certificate of Need (CON) to operate in Manatee County, Florida, representing a significant growth opportunity.

  • Roto-Rooter's paid leads increased 9.4% in Q4 FY25 compared to Q4 FY24.

  • Roto-Rooter's branch commercial revenue increased 1.6% in Q4 FY25 compared to Q4 FY24.

Concerns

5
  • Q4 FY25 fell short of expectations for both subsidiaries, with a $0.70 per share miss.

  • VITAS's revenue growth and EBITDA margin were lower than anticipated due to an overwhelming success in garnering elevated short-stay patient admissions.

  • Roto-Rooter revenue declined 3.7% in Q4 FY25 compared to Q4 FY24.

  • Roto-Rooter's implicit price concessions and credit memos (write-offs) increased by $4 million or 57% in Q4 FY25 compared to Q4 FY24, impacting water restoration revenue.

  • Roto-Rooter's adjusted EBITDA declined 21.1% to $47.5 million in Q4 FY25, with margin decreasing 477 basis points to 21.5%.

Guidance & targets

CategoryTargetConfidence
VITAS Revenue (prior to Medicare Cap)
5.5% to 6.5% increase
high materiality
High
VITAS Average Daily Census (ADC)
3.5% to 4% increase
medium materiality
High
VITAS EBITDA Margin (prior to Medicare Cap)
17.5% to 18%
high materiality
High
VITAS Medicare Cap Billing Limitations
$9.5 million
medium materiality
High
Roto-Rooter Revenue Growth
3% to 3.5%
high materiality
High
Roto-Rooter Adjusted EBITDA Margin
22.5% to 23%
high materiality
High
Adjusted EPS
$23.25 to $24.25
high materiality
High
Effective Corporate Tax Rate on Adjusted Earnings
24.5%
low materiality
High
Diluted Share Count
13.9 million shares
low materiality
High
Consolidated Adjusted Net Income and EBITDA Generation
55% in H2 FY26
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
VITAS Healthcare
Revenue growth was primarily driven by increased days of care and Medicare reimbursement rates, but negatively impacted by acuity mix shift and Medicare Cap accruals. Lower EBITDA margin reflects the impact of admitting more hospital-based short-stay patients for Medicare Cap mitigation. Admissions increased, but median length of stay decreased due to patient mix.
Days of care: 1.3% increaseGeographically weighted average Medicare reimbursement rate increase: 2.2%Acuity mix shift impact on revenue growth: -143 basis pointsMedicare Cap and other contra revenue impact on revenue growth: -20 basis pointsMedicare Cap billing limitation accrued: $2.4 millionFlorida Medicare Cap billing limitation accrued: $0Average revenue per patient day: $208.01Average revenue per patient day YoY change: 86 basis points above prior yearHigh acuity days of care: 2.2% of total days of careHigh acuity days of care YoY change: -32 basis pointsAdjusted EBITDA margin (excluding Medicare Cap): 21.7%Adjusted EBITDA margin YoY change: -79 basis pointsAverage daily census: 22,462 patientsAverage daily census YoY change: 1.3%Hospital directed admissions YoY change: 9.9%Home-based patient admissions YoY change: 4.1%Assisted living facility admissions YoY change: 5.6%Nursing home admissions YoY change: -8.7%Average length of stay: 115.1 daysAverage length of stay YoY change: from 105.5 daysMedian length of stay: 17 daysMedian length of stay YoY change: 1 day less than prior yearFlorida Medicare Cap billing limitation (end of Q4 FY25): less than $2 millionFlorida Medicare Cap billing limitation (end of January '26): $0
$418.8 million1.9%—Adjusted EBITDA $91.6 million
Roto-Rooter
Revenue declined due to significant drops in residential and commercial water restoration and residential drain cleaning, partially offset by growth in plumbing and excavation. Profitability was heavily impacted by increased water restoration write-offs and higher marketing costs.
Branch residential revenue: $155.6 millionBranch residential revenue YoY change: -3.1%Residential plumbing revenue YoY change: 6.3%Residential excavation revenue YoY change: essentially flatResidential water restoration revenue YoY change: -10.3%Residential drain cleaning revenue YoY change: -3.2%Implicit price concessions and credit memos (write-offs) increase: $4 millionImplicit price concessions and credit memos (write-offs) increase YoY: 57%Total write-offs as % of gross revenue (H1 FY25): mid-3%Total write-offs as % of gross revenue (H2 FY25): over 4.5%Total write-offs increase (FY25 vs FY24): $11 millionBranch commercial revenue: $55.2 millionBranch commercial revenue YoY change: 1.6%Commercial excavation revenue YoY change: 10.9%Commercial drain cleaning revenue YoY change: 2%Commercial plumbing revenue YoY change: essentially flatCommercial water restoration revenue YoY change: -20%Adjusted EBITDA margin: 21.5%Adjusted EBITDA margin YoY change: -477 basis pointsTotal leads YoY change: flatPaid leads YoY change: 9.4%Natural leads YoY change: decline (offsetting paid leads)
$210.8 million-3.7%—Adjusted EBITDA $47.5 million

CHE operating KPIs by quarter

CHE operating KPIs stated on its earnings calls, by fiscal quarter
KPIThis call Dec 2025 Q4 FY25 Jun 2026 Q2 FY26Change vs prior quarter
Average daily census VITAS
22.462K In the fourth quarter of 2025, our average daily census was 22,462 patients, an increase of 1.3%. Source: earnings call transcript
23.687K In the second quarter of 2026, our average daily census was 23,687 patients. Source: earnings call transcript
+5.5%
Average length of stay VITAS
115.1 Our average length of stay in the quarter was 115.1 days. Source: earnings call transcript
101.2 Our average length of stay in the quarter was 101.2 days. Source: earnings call transcript
-12.1%
Median length of stay VITAS
17 Our median length of stay was 17 days in the fourth quarter of 2025, 1 day less than the median in the fourth quarter of 2024. Source: earnings call transcript
16 Our median length of stay was 16 days in the second quarter of 2026, a decline of 4 days from the second quarter of 2025. Source: earnings call transcript
-5.9%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Risks & headwinds

Lower revenue growth and EBITDA margin at VITAS due to elevated short-stay patient admissions Q4 FY25

revenue growth and EBITDA margin were lower than anticipated

Mitigation:Refocusing admissions to a more balanced approach between hospital admissions and other pre-admission locations, expected to improve results in H2 2026.

Roto-Rooter revenue decline Q4 FY25

declined 3.7% in the fourth quarter of 2025

Mitigation:New SEO provider, expanding commercial business managers, improving water restoration billing and collections.

Increased water restoration write-offs at Roto-Rooter Q4 FY25

implicit price concessions and credit memos increased at Roto-Rooter by $4 million or 57% compared to the fourth quarter of 2024

Mitigation:Modifications to billing and collection support functions, centralizing water restoration billing and collections, improving documentation through technology.

Higher marketing costs at Roto-Rooter Q4 FY25

The decline in EBITDA margin was caused by higher marketing costs

Mitigation:Focus on driving top-line growth to leverage marketing spend and improve overall profitability.

Negative impact of Google algorithm changes on Roto-Rooter's natural search leads Q4 FY25

The decline in natural leads essentially offset the increase in paid leads

Mitigation:Contracted with a new third-party search engine optimization provider to positively impact natural search results in 2026.

Duplication of costs and investment in technology during Roto-Rooter's billing centralization H1 FY26

some duplication of costs and investment in technology which will cause some marginal headwinds

Mitigation:Expected to be temporary, with financial impact mostly seen in H2 FY26.

Marginal drag from training new commercial business managers at Roto-Rooter H1 FY26

roughly 45-day process to get these positions trained and productive, which also may cause some marginal drag

Mitigation:Temporary drag, expected to lead to improved organic growth in the long term.

What to watch in Q1 FY26

VITAS patient mix rebalancing

Q1 FY26 / H1 FY26
Current Elevated short-stay hospital admissions
Target More balanced mix of hospital and other pre-admission locations

Why it matters

This rebalancing is crucial for VITAS to accelerate revenue growth and improve EBITDA margins as the year progresses.

In mid-January 2026, VITAS management responded to the improved Florida Medicare Cap position by instructing operating personnel to begin the process of refocusing admissions to a more balanced approach between hospital admissions and preadmission -- other preadmission locations. That process is underway.

Find out whether CHE delivers this. Inve re-checks your case every morning.

Q&A highlights

What gives management confidence in 3-3.5% revenue growth for Roto-Rooter in 2026, given recent performance?

Management cited improved paid lead generation (10% increase in last 3 quarters), new SEO provider to improve natural leads, expansion of commercial business managers, and an expected $4M-$6M tailwind from improved water restoration billing/collections. They also noted the Q4 miss was due to specific issues (water restoration, short-stay VITAS admissions) that are being addressed.

“I would characterize our confidence in the 3% to 3.5% revenue growth in '26 based on 3 specific things. As Kevin mentioned, some things we've done to change the lead trajectory, hopefully, to provide some organic growth, but modest organic growth is built in. The increase in commercial sales force will also lead to some more modest organic growth. And then as we've talked about, the water restoration write-offs, we've estimated that of the $11 million that the increase of write-offs of $11 million, we're going to recover maybe half of that this year. So that's a $5.5 million tailwind.”

asked by Joanna Gajuk · answered by Michael Witzeman

3 min read 8 chapters

Detailed narrative

VITAS Florida Medicare Cap Mitigation

VITAS successfully executed strategies to mitigate potential Florida Medicare Cap billing limitations for government fiscal 2026. The Florida Medicare Cap position improved by almost $25 million in Q4 FY25 compared to 2025, with no billing limitation accrued for Florida in Q4 FY25.

As of January 2026, there was no billing limitation in the Florida combined program. This was achieved by increasing hospital-based short-stay admissions, which temporarily impacted revenue and EBITDA margins.

VITAS Admission Rebalancing

In mid-January 2026, VITAS began refocusing admissions to a more balanced approach between hospital admissions and other pre-admission locations. This rebalancing is expected to result in revenue growth and EBITDA margin building over the course of 2026, with financial results mainly reflecting this change in the second half of the year. The goal is to return to a more normal, sustainable organic growth pattern.

VITAS New Market Expansion

VITAS was granted a Certificate of Need (CON) to begin operating in Manatee County, Florida, in December 2025. This county had approximately 3,000 Medicare hospice patients in fiscal 2024, representing a significant growth opportunity. This is the fourth CON awarded to VITAS in the past two years, with previous awards in Pinellas, Marion, and Pasco Counties meeting or exceeding expectations.

Roto-Rooter Revenue Challenges

Roto-Rooter experienced a 3.7% revenue decline in Q4 FY25. Residential revenue decreased 3.1%, primarily due to a 10.3% decline in water restoration and a 3.2% decline in drain cleaning, partially offset by a 6.3% increase in plumbing. Commercial revenue increased 1.6%, but commercial water restoration declined 20%.

Roto-Rooter Water Restoration Write-offs

Implicit price concessions and credit memos (write-offs) for water restoration increased by $4 million or 57% in Q4 FY25 compared to Q4 FY24, and by $11 million in FY25 compared to FY24. This was attributed to increased scrutiny from insurance companies, often using AI, and a reluctance at the branch level to bill for certain services to ensure higher collection rates.

Roto-Rooter Billing and Collection Improvements

In response to the water restoration issues, Roto-Rooter is improving documentation through technology and centralizing billing and collections, which were historically performed at each branch. This centralization is expected to create more expertise and improve results, with financial impact mostly in the second half of 2026, though some cost duplication is expected in H1.

Roto-Rooter Lead Generation and Commercial Growth

Total leads were flat in Q4 FY25, with a 9.4% increase in paid leads offset by a decline in natural leads. Roto-Rooter contracted with a new SEO provider in late December 2025 to improve natural search results. The company is also expanding its commercial business manager program, which has shown encouraging preliminary results, to drive modest organic growth in 2026.

2026 as a Transition Year

Management emphasized that 2026 is expected to be a transition year for both VITAS and Roto-Rooter. Financial results are projected to build over the course of the year, with 55% of consolidated adjusted net income and EBITDA expected to be generated in the second half, reflecting the time needed for strategic initiatives to fully impact performance.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.